CRISPR THERAPEUTICS AG (CRSP) Operating cash flow 2016–2025
CRISPR THERAPEUTICS AG (CRSP) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$345.0MFY2025 · since FY2016: -$52.9M → -$345.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$345.0M | -141.7% |
| FY2024 | -$142.8M | +45.2% |
| FY2023 | -$260.4M | +47.5% |
| FY2022 | -$495.7M | -192.0% |
| FY2021 | $539.0M | +326.1% |
| FY2020 | -$238.4M | -520.6% |
| FY2019 | $56.7M | +158.9% |
| FY2018 | -$96.2M | -37.3% |
| FY2017 | -$70.1M | -32.6% |
| FY2016 | -$52.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice